Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Medifocus, Inc. (OTC: MDFZF).

Full DD Report for MDFZF

You must become a subscriber to view this report.


Recent News from (OTC: MDFZF)

Medifocus, Inc. Announces Successful Completion of FDA Post Approval Study (PAS) for the Prolieve (R) Thermodilatation(TM) System
Prolieve ® is the only Transurethral Thermodilatation™ Therapy for BPH approved by the FDA COLUMBIA, MD and TORONTO, ON / ACCESSWIRE / June 5, 2018 / Medifocus, Inc. (OTCQB: MDFZF; TSX-V: MFS) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medic...
Source: ACCESSWIRE
Date: June, 05 2018 09:20
Medifocus, Inc. Expands Its Reach into the Israeli Market with Amos Gazit Ltd. for Its Prolieve(R) Thermodilatation for BPH Therapy and Announces Significant Debt Conversion into Shares
COLUMBIA, MD / ACCESSWIRE / January 9, 2018 / Medifocus, Inc. (OTCQB: MDFZF; TSX-V: MFS) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medical products encompassing thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer,...
Source: ACCESSWIRE
Date: January, 09 2018 09:22

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-180.0220.020.0220.024,500
2018-12-170.0220.0220.0220.0225,000
2018-12-140.02490.02490.02490.02491,000
2018-12-13N/A0.0236N/AN/A0
2018-12-120.024480.02360.024480.02369,300

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-182,5004,50055.5556Short
2018-12-175,0005,000100.0000Short
2018-12-141,0001,000100.0000Short
2018-12-126,4009,30068.8172Short
2018-12-071,2961,296100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MDFZF.


About Medifocus, Inc. (OTC: MDFZF)

Logo for Medifocus, Inc. (OTC: MDFZF)

Medifocus, Inc. TSXV MFS, OTC MDFZF is a leader in the use of focused microwave energy to treat cancer and other tumors. It owns two fully developed technology platforms with comprehensive US and international patent protection: The Endo thermotherapy Platform a catheter basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The U.S. FDA approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia BPH was developed based on the Endo thermotherapy and is currently generating revenue, and The Adaptive Phased Array APA Microwave Focusing Platform invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company s APA Breast Cancer Treatment System, developed from the APA technology platform has received approval from the U.S. FDA and Health Canada to conduct the pivotal Phase III clinical trials. The Company believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers.

 

Contact Information

 

 

Current Management

  • William Jow / CEO
  • Mirsad Jakubovic / CFO
  • Brian Purkins / Accountant
  • Douglas Liu / Corporate Finance
  • Grant Byron Walsh / Chairman
  • Joseph Shuen Chuen Chan /
  • Augustine Pok Yu Chow /
  • Raymond Tong /

Current Share Structure

  • Market Cap: $5,679,015 - 03/16/2018
  • Issue and Outstanding: 184,984,215 - 03/31/2017
  • Float: 130,000,000 - 03/31/2016

 


Recent Filings from (OTC: MDFZF)

OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: September, 21 2017
Interim Financial Report - Medifocus Financial Statements June 30, 2017
Filing Type: Interim Financial Report - Medifocus Financial Statements June 30, 2017Filing Source: OTC Markets
Filing Date: September, 13 2017
Management Discussion and Analysis - Management Discussion and Analysis for the three months ended June 30, 2017
Filing Type: Management Discussion and Analysis - Management Discussion and Analysis for the three months ended JFiling Source: OTC Markets
Filing Date: September, 13 2017
Annual Report - Medifocus Inc Form 20-F
Filing Type: Annual Report - Medifocus Inc Form 20-FFiling Source: OTC Markets
Filing Date: September, 13 2017

 

 


Daily Technical Chart for (OTC: MDFZF)

Daily Technical Chart for (OTC: MDFZF)


Stay tuned for daily updates and more on (OTC: MDFZF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MDFZF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MDFZF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MDFZF and does not buy, sell, or trade any shares of MDFZF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/